|Articles|February 12, 2008
Altus CEO Resigns
Author(s)BioPharm International Editors
Sheldon Berkle has resigned as president, chief executive officer, and member of the board of directors of Altus Pharmaceuticals, Inc. (Cambridge, MA).
Advertisement
Sheldon Berkle has resigned as president, chief executive officer, and member of the board of directors of Altus Pharmaceuticals, Inc. (Cambridge, MA). David D. Pendergast, PhD, has been appointed to the interim position of executive chairman while the company initiates a search for a new president and chief executive officer.
Newsletter
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on BioPharm International
1
Achieving Real Impact Navigating the Data and Regulatory Barriers to AI Adoption in Bio/pharma
2
How Is AI Transforming Biomanufacturing and Biopharma Workforce Training?
3
How Enzymatic Platforms May Change the Therapeutic RNA Supply Chain
4
RNAnalytics CPHI Interview, Part Two: Nanoparticle Case Studies and Response to US mRNA Pullback
5
